It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical remission compared with 5‐ASA or Sulfasalzine (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in fistula improvement or healing compared with placebo (low certainty).
Azathioprine or 6‐mercaptopurine probably leads to higher steroid sparing effect compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
Azathioprine probably leads to lower clinical remission compared with infliximab (moderate certainty).
Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).
Azathioprine probably leads to lower mucosal healing compared with infliximab (moderate certainty).
5‐ASA showed no clear difference in relapse, drop‐outs classed as relapse, grouped by length of compared with placebo (moderate certainty).
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
The intervention showed no clear difference in induction of remission at 4 weeks (low certainty).
Briakinumab showed no clear difference in failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) compared with placebo (low certainty).
Ustekinumab leads to lower failure to induce clinical response CDAI (≥100 point reduction) compared with placebo (high certainty).
Ustekinumab leads to lower failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100… compared with placebo (high certainty).
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Ustekinumab showed no clear difference in withdrawals due to adverse event compared with placebo (low certainty).